Free Trial

ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals logo
$20.52 -1.22 (-5.60%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ACAD vs. ASND, VTRS, RDY, ROIV, MRNA, QGEN, BBIO, ELAN, VRNA, and RVMD

Should you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Roivant Sciences (ROIV), Moderna (MRNA), Qiagen (QGEN), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

ACADIA Pharmaceuticals vs. Its Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

ACADIA Pharmaceuticals presently has a consensus target price of $29.12, suggesting a potential upside of 40.36%. Ascendis Pharma A/S has a consensus target price of $248.29, suggesting a potential upside of 18.85%. Given ACADIA Pharmaceuticals' higher possible upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65
Ascendis Pharma A/S
1 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.88

ACADIA Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$1.02B3.44$226.45M$1.3315.60
Ascendis Pharma A/S$393.54M32.75-$409.12M-$5.16-40.48

ACADIA Pharmaceuticals has a net margin of 21.80% compared to Ascendis Pharma A/S's net margin of -54.94%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Ascendis Pharma A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals21.80% 14.69% 9.41%
Ascendis Pharma A/S -54.94%N/A -24.31%

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 10 mentions for ACADIA Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.61 beat ACADIA Pharmaceuticals' score of 0.24 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Ascendis Pharma A/S
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Ascendis Pharma A/S on 11 of the 17 factors compared between the two stocks.

Get ACADIA Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACAD vs. The Competition

MetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.50B$3.38B$6.14B$10.45B
Dividend YieldN/A2.30%5.73%4.78%
P/E Ratio15.5922.9585.0627.10
Price / Sales3.44428.48570.65176.64
Price / Cash28.8946.1137.3961.86
Price / Book4.7110.4812.406.66
Net Income$226.45M-$52.47M$3.32B$276.79M
7 Day Performance0.56%-0.91%-0.23%-1.40%
1 Month Performance-13.42%14.63%9.56%5.64%
1 Year Performance37.93%14.38%71.76%37.04%

ACADIA Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACAD
ACADIA Pharmaceuticals
4.435 of 5 stars
$20.52
-5.6%
$29.12
+41.9%
+45.8%$3.47B$1.02B15.45510Analyst Forecast
ASND
Ascendis Pharma A/S
3.105 of 5 stars
$210.83
+3.3%
$244.36
+15.9%
+62.7%$12.57B$490.75M-40.861,017News Coverage
Analyst Forecast
Analyst Revision
Gap Up
VTRS
Viatris
2.2316 of 5 stars
$10.13
-0.6%
$10.40
+2.7%
-15.7%$11.81B$14.74B-3.4932,000News Coverage
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.828 of 5 stars
$14.12
-0.3%
$16.95
+20.0%
-11.0%$11.79B$334.26B21.3927,811News Coverage
ROIV
Roivant Sciences
3.0242 of 5 stars
$16.26
+0.6%
$19.94
+22.6%
+43.0%$11.10B$23.23M-23.23860Insider Trade
MRNA
Moderna
4.2566 of 5 stars
$27.54
-3.3%
$41.81
+51.8%
-51.6%$10.72B$3.24B-3.665,800
QGEN
Qiagen
4.2586 of 5 stars
$46.99
+0.4%
$49.40
+5.1%
+11.5%$10.45B$1.98B27.765,765
BBIO
BridgeBio Pharma
4.3037 of 5 stars
$54.61
+3.3%
$63.94
+17.1%
+123.1%$10.44B$221.90M-13.35400Analyst Revision
ELAN
Elanco Animal Health
2.7807 of 5 stars
$20.68
+0.2%
$18.33
-11.3%
+47.1%$10.27B$4.44B24.059,000Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
1.4602 of 5 stars
$106.91
+0.1%
$109.00
+2.0%
N/A$9.21B$42.28M-107.9930Positive News
RVMD
Revolution Medicines
4.2591 of 5 stars
$46.58
-0.3%
$74.64
+60.2%
+1.2%$8.71B$11.58M-10.35250Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NASDAQ:ACAD) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners